Xu Jiaqin, Huang Chen, Wu Zhenyu, Xu Huilin, Li Jiong, Chen Yuntao, Wang Ce, Zhu Jingjing, Qin Guoyou, Zheng Xueying, Yu Yongfu
Department of Biostatistics, School of Public Health, Fudan University, Shanghai, China.
Shanghai Minhang Center for Disease Control and Prevention, Shanghai, China.
Front Oncol. 2022 May 19;12:875489. doi: 10.3389/fonc.2022.875489. eCollection 2022.
This study aimed to characterize the clinical features of early-stage ovarian cancer (OC) survivors with second primary malignancies (SPMs) and provided a prediction tool for individualized risk of developing SPMs.
Data were obtained from the Surveillance, Epidemiology and End Results (SEER) database during 1998-2013. Considering non-SPM death as a competing event, the Fine and Gray model and the corresponding nomogram were used to identify the risk factors for SPMs and predict the SPM probabilities after the initial OC diagnosis. The decision curve analysis (DCA) was performed to evaluate the clinical utility of our proposed model.
A total of 14,314 qualified patients were enrolled. The diagnosis rate and the cumulative incidence of SPMs were 7.9% and 13.6% [95% confidence interval (CI) = 13.5% to 13.6%], respectively, during the median follow-up of 8.6 years. The multivariable competing risk analysis suggested that older age at initial cancer diagnosis, white race, epithelial histologic subtypes of OC (serous, endometrioid, mucinous, and Brenner tumor), number of lymph nodes examined (<12), and radiotherapy were significantly associated with an elevated SPM risk. The DCA revealed that the net benefit obtained by our proposed model was higher than the all-screening or no-screening scenarios within a wide range of risk thresholds (1% to 23%).
The competing risk nomogram can be potentially helpful for assisting physicians in identifying patients with different risks of SPMs and scheduling risk-adapted clinical management. More comprehensive data on treatment regimens and patient characteristics may help improve the predictability of the risk model for SPMs.
本研究旨在描述早期卵巢癌(OC)幸存者发生第二原发性恶性肿瘤(SPM)的临床特征,并提供一种预测个体发生SPM风险的工具。
数据来源于1998 - 2013年的监测、流行病学和最终结果(SEER)数据库。将非SPM死亡视为竞争事件,使用Fine和Gray模型及相应的列线图来识别SPM的危险因素,并预测初始OC诊断后的SPM概率。进行决策曲线分析(DCA)以评估我们提出的模型的临床实用性。
共纳入14314例合格患者。在中位随访8.6年期间,SPM的诊断率和累积发病率分别为7.9%和13.6%[95%置信区间(CI)= 13.5%至13.6%]。多变量竞争风险分析表明,初始癌症诊断时年龄较大、白人种族、OC的上皮组织学亚型(浆液性、子宫内膜样、黏液性和勃勒纳瘤)、检查的淋巴结数量(<12个)以及放疗与SPM风险升高显著相关。DCA显示,在广泛的风险阈值范围(1%至23%)内,我们提出的模型获得的净效益高于全筛查或不筛查的情况。
竞争风险列线图可能有助于协助医生识别具有不同SPM风险的患者,并安排风险适应性临床管理。关于治疗方案和患者特征的更全面数据可能有助于提高SPM风险模型的预测能力。